For IPO Boutique's "scale of 1 to 5" BUY rating on Argos Therapeutics, and our comprehensive analysis, click the "Buy Market Research" link.
About Argos Therapeutics (adapted from Argos Therapeutics prospectus): Argos is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on their proprietary technology platform called Arcelis. Using biological components obtained from each patient, their Arcelis-based immunotherapies employ a specialized white blood cell, called a dendritic cell, to activate an immune response that is specific to the patient's disease.
This description is adapted from Argos prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus..
Share this IPO Profile:
IPO Boutique aggregates information on public companies and private companies, such as Argos "ARGS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.